Petros D. Grivas, Stephanie Daignault, Scott T. Tagawa, David M. Nanus, Walter M. Stadler, Robert Dreicer, Manish Kohli, Daniel P. Petrylak, David J. Vaughn, Kathryn A. Bylow, Steven G. Wong, Joseph L. Sottnik, Evan T. Keller, Mahmoud Al-Hawary, David C. Smith and Maha Hussain Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma Cancer 120
Version of Record online: 18 NOV 2013 | DOI: 10.1002/cncr.28477
The authors investigated the role of maintenance sunitinib in patients with advanced urothelial carcinoma. Maintenance sunitinib did not improve the 6-month progression rate and appeared to have only modest activity.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field